Home
About Us
Help and Support
Subscribe
Company Analyst
Financial Analyst
Pipeline Analyst
Archives
Tools
Log In
Print this
BIIB057, PRT062607, PRT2607 (formerly P505-15)
print preview
bookmark
share with colleague
General Information
Company
Portola Pharmaceuticals Inc.
Description
Oral spleen tyrosine kinase (SYK) inhibitor
Molecular Target
Spleen tyrosine kinase (SYK)
Mechanism of Action
Syk kinase inhibitor
Product Summary: Number of Indications in each Phase of Development by Disease Category
More
Product Details
Disease Category
Standard Indication
Indication Details
Partners
Milestones
Latest Stage of Development
More
Archive Items are loading
Set Email Alert
dummy